This promotional survey has been organised, funded and reviewed by CSL Seqirus for GB healthcare professionals only.
Prescribing information:
Adjuvanted trivalent influenza vaccine▼available here
Cell-based influenza vaccine▼available here
This survey is anonymous, and no personal information will be collected. Responses will be used for internal insights only.
If your response includes details of an adverse event, side effect, or product quality complaint related to our products, we are legally required to collect and report certain information, including your contact details, to meet pharmacovigilance obligations.
To report an adverse event or product complaint, please use the official reporting channels:
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events relating to CSL Seqirus products should also be reported to Seqirus UK Limited on 01748 828816.
The objective of this survey is to gather insights and feedback on the toolkits which may assist pharmacists in identifying patients potentially suitable for flu vaccination using the Proscript Connect PMR system.
This survey is anonymous, and your responses cannot be traced back to you individually.
GBR-NOPR-25-0044 | October 2025